Impact of the COVID-19 Pandemic on Global Anticoagulant Sales: A Cross-Sectional Analysis Across 39 Countries

Inmaculada Hernandez, Mina Tadrous, Jared W. Magnani, Jingchuan Guo, Katie J. SudaAmerican 2021 · DOI · OpenAlex

Introduction

The COVID-19 pandemic presented a dual challenge to hematological care. Early clinical observations identified a significantly increased risk of life-threatening thrombosis in infected patients, leading to revised medical guidelines. These guidelines emphasized the use of injectable anticoagulants (such as heparin) for hospitalized patients and encouraged a transition for outpatients from Vitamin K antagonists (e.g., warfarin), which require frequent in-person monitoring, to Direct Oral Anticoagulants (DOACs). This study investigates whether these clinical recommendations translated into measurable shifts in the global pharmaceutical market and quantifies the resulting supply chain "shock."

Methods and Data

Researchers utilized the IQVIA MIDAS® database, a comprehensive repository of retail and hospital drug purchase records spanning 39 countries from August 2014 to August 2020. Drugs were categorized into three primary classes: Injectable anticoagulants, Vitamin K antagonists, and DOACs.

The primary metric was the number of units sold per 1,000 population per month. An interrupted time-series analysis (ITS) was employed to evaluate the impact of the March 2020 pandemic declaration. This quasi-experimental design allowed researchers to account for pre-existing trends while measuring immediate "level changes" and subsequent shifts in the slope of sales trends.

Results

The analysis revealed a significant immediate surge in anticoagulant sales following the pandemic declaration. On average, countries saw an 11% increase in total anticoagulant units purchased between March and August 2020 compared to the same period in 2019.

Global anticoagulant sales trends (2014-2020) showing the impact of the March 2020 pandemic declaration.

DOACs exhibited the most pronounced growth. While already trending upward at 26% annually prior to the pandemic, they experienced a statistically significant level change increase in March 2020 ($p = 0.019$). This spike likely reflects a combination of patient stockpiling and a rapid clinical pivot toward "socially distanced" medications that do not require routine blood testing. Conversely, global sales for injectable anticoagulants remained surprisingly stable. This "injectable paradox" is attributed to a balancing effect: increased demand for treating severe COVID-19 was offset by the widespread cancellation of elective surgeries, which typically consume significant quantities of these drugs.

Geographic Variation

The impact of the pandemic was not uniform across the globe, with significant divergence observed at the national level.

Percentage change in anticoagulant sales by drug class and country (Mar-Aug 2020 vs. Mar-Aug 2019).

Mexico and Russia recorded the highest increases in total sales, both near 40%. In Russia, this surge was linked to specific emergency government regulations regarding pharmaceutical distribution. In contrast, the United Kingdom was the only high-population nation to see a slight decrease (-2%) in total sales. Notable outliers in specific drug classes included Australia, which saw a 55% surge in injectables, and the United States, which experienced a 22% decrease in injectable sales—likely reflecting a more aggressive suspension of non-COVID hospital services.

Discussion

While this study highlights major shifts in the global anticoagulant market, several limitations remain. Sales data reflects procurement rather than actual patient administration; thus, it cannot distinguish between clinical use and institutional stockpiling. Furthermore, the lack of patient-level "indication" data prevents researchers from confirming whether these purchases were directly linked to COVID-19 treatment or other conditions.

Future research utilizing electronic health records (EHR) will be essential to determine if these market shifts correlated with improved patient outcomes or if they primarily represent inefficiencies and panic-buying within the global pharmaceutical supply chain.

Summary updated

BibTeX
@inproceedings{hernandez2021impact,
  author = {Inmaculada Hernandez and Mina Tadrous and Jared W. Magnani and Jingchuan Guo and Katie J. Suda},
  title = {{Impact of the COVID-19 Pandemic on Global Anticoagulant Sales: A Cross-Sectional Analysis Across 39 Countries}},
  booktitle = {American},
  year = {2021},
  doi = {10.1007/s40256-021-00475-9},
}
Figure